



This Programme is funded by the European Union

GUIDELINES ON COMPILING COUNTRY SITUATION PROFILE (DRUG SITUATION)



2025

Guidelines on Compiling Country Situation Profile (Drug Situation)



This Programme is funded by the European Union

The publication was funded by the European Union. Its contents are the sole responsibilities of CADAP Programme and do not necessarily reflect the views of European Union

1.	Introduction and Guide.....	3
2.	Basic data.....	4
3.	Drug use in the general population, including young people	6
4.	Prophylaxis.....	9
5.	Problematic Drug Use	9
6.	Demand for and response to drug-related treatment.....	11
7.	Drug-Related Infectious Diseases	13
	HIV	13
	Viral hepatitis and others (syphilis).....	14
8.	Drug-related deaths and deaths among drug users	16
9.	Harm Reduction Responses	16
10.	Drug Markets and Drug-Related Crime.....	17
11.	National legislation on illegal surfactants	20
12.	National drug strategies	20
13.	Coordination mechanisms in the field of drugs	20
14.	Links	21

1. Introduction and Guide

The subsequent pages present a set of templates to assist in the compilation of a Country Profile. The data used to prepare such a document should be from the year preceding its compilation, i.e. Country Profile 2023 should incorporate data up to 31 December 2023.

The table of contents provides the structure and headings that should be included in the country profile. Each section of this guidelines incorporates tables and questionnaires to aid the process of data collating.

The aim of preparing this document is:

- To update country information on the CADAP and EMCDDA websites.
- To provide the European Monitoring Centre for Drugs and Drug Dependence (EMCDDA) and other international organizations with current country information.
- To compile a Regional Overview Report based on these country profiles.

2. Basic data

	Year [rrrr]	[Short name of country] [] sq.km	Source [Name of institution – title and year of source]
Territory	[rrrr]	[] sq.km	[Name of institution – title and year of source]
Population	[rrrr]	[]	[Name of institution – title and year of source]
Gross Domestic Product per Capita by Purchasing Power Standard	[rrrr]	€ [xxx], i.e. \$[xxx]	[Name of institution – title and year of source]
Income Distribution Inequality (Gini coefficient ¹)	[rrrr]	The range of the Gini index is between 0 and 1 (0% and 100%), where 0 indicates excellent uniformity and 1 (100%) indicates maximum irregularity.	[Name of institution – title and year of source]
Unemployment Rate	[rrrr]	[x.xx]%	[Name of institution – title and year of source]
Prison population	[rrrr]	[xxx]	[Name of institution – title and year of source]
Population below the poverty line	[rrrr]	[xx.x]%	[Name of institution – title and year of source]
Per capita income or consumption as a percentage share	[rrrr]	Income: [lowest [xx% - xx.x]%; highest [xx% - xx.x]%]	[Name of institution – title and year of source]

¹ The Gini coefficient is a measure of income inequality within a nation. It ranges from 0 to 1, where 0 represents perfect equality (everyone has the same income) and 1 indicates perfect inequality (one person has all the income, and everyone else has none).

The text outlines the formatting of a document. It indicates that the subsequent text is divided into chapters and paragraphs without any **bold** font, *italics*, or underlining

The next section of the document may include tables, charts, or maps

Table example: [Text]

[Text]	[absolute figures]	[percentage]
[Text]	[xxxx]	[xxx]%
[Text]	[xxxx]	[xxx]%

3. Drug use in the general population, including young people

[Text]

[If necessary, use a bulleted list in the following form]:

- Text;
- Text;
- Text.

[Text]

[Typical tables or charts – add as many as required]

RESEARCH

Drug use among the general population: population aged 15-64 years or similar.

Specify the age range: [-], **Geographic coverage:** Whole country/province. If it is a regional study, please specify the coverage in detail: [-], Year of study: [-]

Narcotic	Lifetime prevalence (%)			Prevalence within the last year (%)		
	Men	Women	Total	Men	Women	Total
Any illegal drugs						
Opiates (heroin)						
Cannabis						
Cocaine						
Ecstasy						
Amphetamines (e.g. Captagon)						
Volatile solvents						
Other drugs, please specify:						
Any injecting drug						

Drug Use Among Schoolchildren (the latest available study with national (or "near-national") coverage, similar to ESPAD)

Specify in detail the coverage: [-], Age range of the examined: [-], Year: [-]

Narcotic	Lifetime prevalence (%)			Prevalence within the last year (%)		
	Men	Women	Total	Men	Women	Total
Any illegal drugs						
Opiates (heroin)						
Cannabis						
Cocaine						
Ecstasy						
Amphetamines (e.g. Captagon)						
Volatile solvents						
Other drugs, please specify:						
Any injecting drug						

NARCOLOGICAL REGISTRATION

Number of persons diagnosed with drug addiction (substance abuse) and alcoholism registered for clinical monitoring, categorized by the type of primary drug, for the years 2018-2023 [specify the period covered]:

Year	Heroin	Other opiates	Cannabinoids	Other illicit drugs	Polydrug addiction	Total Illegal Drugs			Alcohol as the main drug			
	M	F	M	F	M	F	M	F	Total	M	F	Total
2018												
2019												
2020												
2021												
2022												
2023												

Number of individuals diagnosed with drug addiction (toxicomania) registered for clinical monitoring by type of primary drug from [specify the years covered], by age categories (if age groups vary, use similar age ranges as those below and indicate the age groups); DO NOT INCLUDE cases where alcohol is the primary drug.

Years	0-15		15-34		35-64		64+		Total	
	M	F	M	F	M	F	M	F	M	F
2017										
2018										
2019										
2020										
2021										
2023										

4. Prophylaxis

[Text]

[Use a bulleted list in the following form, if necessary:

- Text;
- Text;
- Text;
- Text.]

[Text]

5. Problematic Drug Use

[Text]

[Use a bulleted list in the following form, if necessary:

- Text;
- Text;
- Text;
- Text.]

[Text]

[Typical tables or graphs - add as many as required]

ASSESSMENT OF PROBLEMATIC DRUG USE

Latest Available Assessment of the extent of Problematic Drug Use (DOP)

Parameter	Parameter value or description
Year of assessment	
Definition of PNP (e.g. IDUs or problem opiate users or heroin users)	
Assessment method (e.g. multiplier method or capture-recapture)	
Data sources used (specify if research data or administrative data were used for the assessment)	
Central estimate value (absolute estimated number of drug users)	
95% Confidence Interval: Lowest Threshold	
95% Confidence Interval: Highest Threshold	

Previous available estimates of the magnitude of problematic drug use (DOP)

Parameter	Parameter value or description
Year of assessment	
Definition of PNP (e.g. IDUs or problem opiate users or heroin users)	
Assessment method (e.g. multiplier method or capture-recapture)	
Data sources used (specify if research data or administrative data were used for the assessment)	
Central estimate value (absolute estimated number of drug users)	
95% Confidence Interval: Lowest Threshold	
95% Confidence Interval: Highest Threshold	

6. Demand for and response to drug-related treatment

[Text]

[Use a bulleted list in the following form, if necessary:

- Text;
- Text;
- Text.

[Text]

[Typical tables or charts - add as many as required]

Availability of treatment methods. Rating: Full (available to all consumers throughout the country) – Medium (available to some consumers and/or in a certain part of the country) – Weak (almost unavailable and/or available in very limited areas) – Not available

Method	Availability (estimate)
Detoxification	
Outpatient non-pharmacological treatment	
Inpatient non-pharmacological treatment	
Opioid Substitution Therapy	
Psychological support and treatment	
Social Rehabilitation	

Number of medical institutions	
Type of institution	Quantity
Narcological Dispensary	
Narcological office	
Adolescent Narcological Cabinet	
Narcological Hospital	
Drug Treatment Beds	
Other health care facilities – NGOs	
Other medical institutions – private	

Number of people in treatment for drug dependence

Outpatient / Stationary: [-], Public / Private: [-]

Year	Underwent treatment for the first time in their lives					All Treated Patients					Total	Of all women
	Heroin	Other opiates	Cannabis	Stimulants	Other	Total	Heroin	Other opiates	Cannabis	Stimulants	Other	
2018												
2019												
2020												
2021												
2022												
2023												

Number of sites and number of people receiving substitution therapy					Methodological information – refers to a period of time or a specific time – specify a time period or a specific time?
Year	Number of sites providing substitution therapy	Number of people receiving substitution therapy	Number of people receiving	Methodological information – refers to a period of time or a specific time – specify a time period or a specific time?	
2018					
2019					
2020					
2021					
2022					
2023					

7. Drug-Related Infectious Diseases

[Text]

HIV

[Text]

[Use a bulleted list in the following form, if necessary:

- Text;
- Text;
- Text.]

[Text]

[Typical tables or graphs - add as many as required]

Registered number of HIV infections – total and among IDUs

Year	Number of new HIV infections detected in the country	Of these, injecting drug users
2018		
2019		
2020		
2021		
2022		
2023		

HIV seroprevalence (approx. DEN)

Year	Sample size (total number tested)	Number of infected people (total number of infected people)	% of infected	Methodological information	Miscellaneous notes
			Sampling	Geographical coverage (national or regional study – which regions)	
2018					
2019					
2020					
2021					
2022					
2023					

Viral hepatitis and others (syphilis)

[Text]

[Use a bulleted list in the following form, if necessary:

- Text;
- Text;
- Text.]

[Text]

[Typical tables or graphs - add as many as required]

HCV serological prevalence (note DEN)

Year	Sample size (total number tested)	Number of infected people (total number of infected people)	% of infected	Methodological information	
			Sampling	Geographical coverage (national or regional study – which regions)	Miscellaneous notes
2018					
2019					
2020					
2021					
2022					
2023					

Syphilis seroprevalence (DEN note)

Year	Sample size (total number tested)	Number of infected people (total number of infected people)	% of infected	Methodological information	
			Sampling	Geographical coverage (national or regional study – which regions)	Miscellaneous notes
2018					
2019					
2020					
2021					
2022					
2023					

8. Drug-related deaths and deaths among drug users

[Text]

[Use a bulleted list in the following form, if necessary:

- Text;
- Text;
- Text.]

[Text]

[Typical tables or graphs - add as many as required]

Drug overdoses (direct Drug-Related Deaths)

Year	Opiate overdose	Other overdoses	Total number of overdoses
2018			
2019			
2020			
2021			
2022			
2023			

9. Harm Reduction Responses

[Text]

[Use a bulleted list in the following form, if necessary:

- Text;
- Text;

- Text.
[Text]

[Typical tables or graphs - add as many as required]

Number of harm reduction centres (drop-in centres) and number of people receiving substitution therapy

Year	Number of harm reduction centres (drop-in centers, trust points, etc.)	Of these, the number of centres conducting needle and syringe exchange programmes	Number of PTS contacts (i.e., number of visits)	Number of syringes distributed
2018				
2019				
2020				
2021				
2022				
2023				
2014				
2015				
2016				
2017				

10. Drug Markets and Drug-Related Crime

[Text]

[Use a bulleted list in the following form, if necessary:

- Text;
- Text;
- Text.

[Text]

Drug-related offences – drug-related criminal offences registered by the police (people arrested in connection with drug-related offences)

Year	Number of drug-related crimes		Number of persons involved
	Total	Of these, related to personal possession or consumption	
2018			
2019			
2020			
2021			
2022			
2023			

Seizure of drugs

Year	Heroin		Opium		Koknar		Cannabis Plant		Other cannabis		Other	
	Number of withdrawals	Volume (kg, pieces)										
2018												
2019												
2020												
2021												
2022												
2023												

Drug prices – retail and wholesale (in US dollars and euros)

Specify the calculation method: e.g. average, accurate, described (most commonly reported), regular price...

Year	Heroin		Marijuana	
	Wholesale for 1 kg		Retail per 1 g	
	Dollars	Euro	Dollars	Euro
2018				
2019				
2020				
2021				
2022				
2023				

Purity of the drug

Year	Heroin (% diacetylmorphine)		Marijuana (% tetrahydrocannabinol)	
	Wholesale	Retail	Wholesale	Retail
2018				
2019				
2020				
2021				
2022				
2023				

Please add a comment to the price in cases where the purity of the drug is known.

11. National legislation on illegal surfactants

[Use a bulleted list in the following form, if necessary:

- Text;
- Text;
- Text.]

[Text]

12. National drug strategies

1. [A numbered list may be used here.]
2. Numbered text.]

[Text]

[Use a bulleted list in the following form, if necessary:

- Text;
- Text;
- Text.]

[Text]

13. Coordination mechanisms in the field of drugs

[Text]

[Use a bulleted list in the following form, if necessary:

- Text;
- Text.]

- Text.
[Text]

14. Links

1. [For in-text citations, please use numbers in parentheses (in EndNote, use the Vancouver standard, which will create a list of references automatically)]
2. [Text.]